Preclinical evaluation of a novel allosteric IL-1R inhibitor (rytvela) for the prevention of perinatal inflammation-induced fetal injury

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1145295

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Interleukin-1 (IL-1) is a potent inflammatory protein involved in many inflammatory disorders, including preterm birth (PTB). Blocking the actions of IL-1 in pregnancies at risk of delivering preterm may protect the fetus from PTB and the long-term harm of exposure to inflammation before birth. Using four different models of antenatal inflammation, we will explore the use of a new IL-1 inhibitor to see if it blocks inflammation ‘in utero’ and improve neonatal health and development.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $1,377,827.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Paediatrics and Reproductive Medicine not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cytokines | fetus | inflammation | placenta | pregnancy complications

Related Links